Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Por um escritor misterioso
Descrição
Dupilumab demonstrates long-term safety, efficacy among children
Frontiers Severe pediatric asthma therapy: Dupilumab
Full article: Dupilumab in the management of moderate-to-severe
Dupilumab pharmacokinetics and effect on type 2 biomarkers in
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
DUPIXENT® (dupilumab) in Moderate-to-Severe Asthma
DUPIXENT® (dupilumab) Pediatric Asthma Efficacy
Dupilumab-improved lung function lasts in children with moderate
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension
Developments in the Management of Severe Asthma in Children and
DUPIXENT® (dupilumab) Dosage & Administration Information
Dupilumab pharmacokinetics and effect on type 2 biomarkers in
Dupilumab demonstrates long-term safety, efficacy among children
Dupilumab in children aged 6 months to younger than 6 years with
Assessment of dupilumab in children with moderate‐to‐severe type 2
de
por adulto (o preço varia de acordo com o tamanho do grupo)
/media/movies/covers/2016/05/meu-nome-e-yu-ming_t74564.jpg)
